Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPTeR: Nivolumab in Metastatic Renal Cell Cancer
NCT02446860Phase 2Terminated
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Apr 2015
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in renal cell carcinoma (RCC), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Safety profile of Nivolumab. Started Apr 2015; status: terminated.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02446860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02446860.